Psoriasis vulgaris, psoriatic arthritis and rheumatoid arthritis are chronic inflammatory and immune-mediated disorders, widely distributed in the population and induced by several environmental factors in genetically predisposed individuals. Different therapies are currently used to treat these diseases. Since these pathologies are characterized by an altered production of proinflammatory cytokines and chemokines, and biological therapy is based on the development of monoclonal antibodies or recombinant proteins against these molecules, this therapy represents an important option. Nevertheless, it was recently reported that biological agents have been associated with serious life-threatening infections. This article aims to summarize literature data on viral reactivation risk that clinicians need to take into account when selecting the most appropriate biological therapy for such patients.
GuentherLC. Combination therapy of biologics with traditional agents in psoriasis. Skin Ther Lett2011; 16:1–3.
5.
CassellSKavanaughA. Psoriatic arthritis: pathogenesis and novel immunomodulatory approaches to treatment. J Immune Based Ther Vaccines2005; 3:6.
6.
McInnesIBSchettG. The pathogenesis of rheumatoid arthritis. N Eng J Med2011; 365:2205–19.
7.
ScottDL. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther2012; 91:30–43.
8.
PatelTGordonKB. Adalimumab: efficacy and safety in Psoriasis and rheumatoid arthritis. Dermatol Ther2004; 17:427–31.
9.
BuccolieroGLoneroGRomanelliCLoperfidoPRestaF. Varicella zoster virus encephalitis during treatment with anti-tumor necrosis factor-α agent in a psoriatic arthritis patient. New Microbiol2010; 33:271–74.
10.
KeystoneECKavanaughAFSharpJTTannenbaumHHuaYTeohLSFischkoffSAChartashEK. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheumatol2004; 50:1400–11.
11.
PappKAGriffithsCEGordonKLebwohlMSzaparyPOWasfiYChanDHsuMCHoVGhislainPDStroberBReichK. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from five years of follow-up. Br J Dermatol2013; 168:844–54.
12.
KoskinasJTampakiMDoumbaPPRallisE. Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in an HBsAg negative anti-HBs positive patient. Br J Dermatol2012; 168:679–80.
13.
MastroianniCMLichtnerMCittonRDel BorgoCRagoAMartiniHCiminoGVulloV. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol2011; 17:3881–87.
14.
FaillaVNikkelsAF. Ustekinumab and herpes zoster. Dermatology2011; 222:119–22.
15.
GürcanHMKeskinDBSternJNNitzbergMAShekhaniHAhmedAR. A review of the current use of rituximab in autoimmune diseases. Int Immunopharmacol2009; 9:10–25.
16.
BergerJRHouffSAMajorEO. Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs2009; 1:583–89.
GravesJENunleyKHeffernanMP. Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol2007; 56:e55–79.
19.
De KeyserF. Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective. Curr Rheumatol Rev2011; 7:77–87.
20.
ColaciMSebastianiMSandriGMeacciMFerriC. Epstein-Barr virus reactivation after Infliximab in Rheumatoid Arthritis: a case report. Case Rep Infect Dis2011; 2011:530568.
21.
Torre-CisnerosJdel CastilloMCastónJJCastroMCPérezVCollantesE. Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis. Rheumatol2005; 44:1132–35.
22.
KomatsudaAWakuiHNimuraTSawadaKI. Reversible infliximab-related lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis. Modern Rheumatol2008; 18:315–18.
23.
WegerW. Current status and new developments in the treatment of Psoriasis and Psoriatic arthritis with biological agents. Br J Pharmacol2010; 160:810–20.
24.
ThorlundKDruytsEAviña-ZubietaJAMillsEJ. Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis. Biologics2012; 6:417–27.
25.
ListingJGerholdKZinkA. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2013; 52:53–61.
